Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.48 +14.9%	$3.03	$1.89 ▼ $4.70	$1.16B	0.62	3.62 million shs	11.57 million shs
COGT Cogent Biosciences	$12.49 +2.4%	$7.22	$3.72 ▼ $12.94	$1.39B	1.88	1.63 million shs	3.68 million shs
PAHC Phibro Animal Health	$29.41 -1.1%	$25.63	$16.16 ▼ $31.80	$1.21B	0.75	224,464 shs	353,025 shs
RCKT Rocket Pharmaceuticals	$3.04 -9.0%	$3.65	$2.19 ▼ $26.98	$356.66M	0.67	2.32 million shs	4.00 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-3.94%	-8.24%	+25.00%	+61.16%	+15.73%
COGT Cogent Biosciences	+2.87%	+12.44%	+60.10%	+179.18%	+35.86%
PAHC Phibro Animal Health	-2.65%	-4.53%	+21.60%	+71.95%	+56.31%
RCKT Rocket Pharmaceuticals	+16.78%	+5.70%	+22.79%	-47.24%	-85.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.333 of 5 stars	3.5	1.0	0.0	0.0	2.7	3.3	0.0
COGT Cogent Biosciences	3.5445 of 5 stars	4.4	3.0	0.0	0.0	2.8	1.7	0.6
PAHC Phibro Animal Health	3.9512 of 5 stars	0.9	4.0	2.5	1.1	2.7	3.3	2.5
RCKT Rocket Pharmaceuticals	4.8495 of 5 stars	4.2	3.0	0.0	4.7	1.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.75	95.31% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	49.72% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-17.04% Downside
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	511.84% Upside

Current Analyst Ratings Breakdown

Latest RCKT, PAHC, ABCL, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
7/7/2025	COGT Cogent Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $28.00
7/7/2025	COGT Cogent Biosciences	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	46.37	N/A	N/A	$3.58 per share	1.25
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
PAHC Phibro Animal Health	$1.02B	1.17	$2.04 per share	14.45	$6.34 per share	4.64
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	N/A	N/A	N/A	-737.56%	-15.98%	-12.38%	8/7/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	37.71	14.00	0.51	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest RCKT, PAHC, ABCL, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	N/A	N/A	N/A	$7.55 million	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.54	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.63%	N/A	61.54%	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest RCKT, PAHC, ABCL, and COGT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
COGT Cogent Biosciences	N/A	5.13	5.13
PAHC Phibro Animal Health	2.67	2.91	1.23
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
COGT Cogent Biosciences	N/A
PAHC Phibro Animal Health	99.34%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
COGT Cogent Biosciences	7.29%
PAHC Phibro Animal Health	50.07%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

RCKT, PAHC, ABCL, and COGT Headlines

Recent News About These Companies

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

July 18 at 12:31 PM | zacks.com

Deadline Alert: Rocket Pharmaceuticals, Inc. ...

July 18 at 12:08 PM | gurufocus.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. ...

July 18 at 9:31 AM | gurufocus.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors - Contact Levi & Korsinsky

July 18 at 8:45 AM | prnewswire.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 17 at 6:05 PM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT

July 17 at 4:15 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 17 at 4:00 PM | globenewswire.com

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action– Hagens Berman

July 17 at 3:07 PM | globenewswire.com

Rocket Pharmaceuticals gets FDA RMAT status for heart disorder therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals stock surges after FDA grants key designation

July 17 at 1:42 PM | investing.com

Rocket Pharmaceuticals Shares Jump After FDA Grants Accelerated Review Status to Gene Therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 17 at 12:00 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

July 17 at 10:00 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKT

July 17 at 9:00 AM | prnewswire.com

NASDAQ: RCKT INVESTOR ALERT: Berger Montague Advises Rocket Pharmaceuticals (RCKT) Investors of August 11, 2025 Deadline

July 17 at 8:36 AM | globenewswire.com

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

July 17 at 7:00 AM | businesswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Brokerages

July 17 at 2:46 AM | marketbeat.com

B2B Rocket joins publicly traded tech powerhouse in move to scale smarter and faster

July 16 at 5:38 PM | manilatimes.netM

Virgin Islands Students Complete Elite NASA-Style Training at U.S. Space & Rocket Center

July 16 at 5:38 PM | viconsortium.comV

Army Unit in Hawaii Receives Long-range Rocket Artillery for Pacific Operations

July 16 at 5:38 PM | news.usni.orgN

Rocket Pharmaceuticals, Inc. (RCKT) Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 11, 2025 to Discuss Your Rights

July 16 at 4:44 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, PAHC, ABCL, and COGT Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.48 +0.58 (+14.87%)

Closing price 04:00 PM Eastern

Extended Trading

$4.50 +0.02 (+0.47%)

As of 08:00 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cogent Biosciences NASDAQ:COGT

$12.49 +0.29 (+2.38%)

Closing price 04:00 PM Eastern

Extended Trading

$12.48 -0.01 (-0.08%)

As of 07:56 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$29.41 -0.32 (-1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$29.44 +0.03 (+0.10%)

As of 07:04 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.04 -0.30 (-8.98%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.04 (+1.32%)

As of 07:53 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time